Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases

Gil Aizik, Etty Grad, Gershon Golomb

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Major advances have been achieved in understanding the mechanisms and risk factors leading to cardiovascular disorders and consequently developing new therapies. A strong inflammatory response occurs with a substantial recruitment of innate immunity cells in atherosclerosis, myocardial infarction, and restenosis. Monocytes and macrophages are key players in the healing process that ensues following injury. In the inflamed arterial wall, monocytes, and monocyte-derived macrophages have specific functions in the initiation and resolution of inflammation, principally through phagocytosis, and the release of inflammatory cytokines and reactive oxygen species. In this review, we will focus on delivery systems, mainly nanoparticles, for modulating circulating monocytes/monocyte-derived macrophages. We review the different strategies of depletion or modulation of circulating monocytes and monocyte subtypes, using polymeric nanoparticles and liposomes for the therapy of myocardial infarction and restenosis. We will further discuss the strategies of exploiting circulating monocytes for biological targeting of nanocarrier-based drug delivery systems for therapeutic and diagnostic applications.

Original languageEnglish
Pages (from-to)868-882
Number of pages15
JournalDrug Delivery and Translational Research
Issue number4
StatePublished - 1 Aug 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017, Controlled Release Society.


  • Drug delivery systems
  • Liposomes
  • Monocyte subpopulations
  • Monocytes
  • Polymeric nanoparticles
  • Vascular injury


Dive into the research topics of 'Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases'. Together they form a unique fingerprint.

Cite this